Receive 30% off all Monoclonal IHC antibodies with code "MONO-IHC-30"! Offer valid for US customers and available internationally through distributors.

phospho-Parkin (Ser65) Polyclonal Antibody

Applications

  • WB
  • ELISA
  • IHC-P
  • IHC-F
  • IF(ICC)
  • IF

Reactivity

  • Human
  • Mouse

Predicted Reactivity

  • Cow
  • Sheep
  • Pig
  • Horse
  • Monkey
Overview
Catalog # bs-19882r
Product Name phospho-Parkin (Ser65) Polyclonal Antibody
Applications WB, ELISA, IHC-P, IHC-F, IF(ICC), IF
Reactivity Human, Mouse
Predicted Reactivity Cow, Sheep, Pig, Horse, Monkey
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthesised phosphopeptide derived from human Parkin around the phosphorylation site of Ser65.
Modification Site Ser65
Clonality Polyclonal
Clone # #REF!
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Store at -20C for 12 months.
Target
Gene ID 5071
Swiss Prot O60260
Synonyms Parkin (phospho S65); p-Parkin (phospho S65); AR JP; E3 ubiquitin ligase; E3 ubiquitin protein ligase parkin; E3 ubiquitin-protein ligase parkin; FRA6E; LPRS 2; LPRS2; PARK 2; PARK2; Parkin 2; Parkinson disease (autosomal recessive juvenile) 2; Parkinson disease (autosomal recessive, juvenile) 2, parkin; Parkinson disease protein 2; Parkinson juvenile disease protein 2; Parkinson protein 2 E3 ubiquitin protein ligase; Parkinson protein 2, E3 ubiquitin protein ligase (parkin); PDJ; PRKN 2; PRKN; PRKN2; PRKN2_HUMAN; Ubiquitin E3 ligase PRKN.
Background Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene.
Application Dilution
WB
ELISA
IHC-P
IHC-F
IF(ICC)
IF